Sunday, June 28, 2020 7:27:42 PM
Pursuant to the obtained May FDA/EUA approval, as confirmed via e-mails from CEO Melissa Waterhouse, ABMC has shipped over 1.0 million test kits and made $436,000.00 in profits. PROFITS, MEANING THEY HAVE A 43% PROFIT MARGIN. The aforementioned million test kits are not inclusive of the pre-approval test kits sold by ALERGINICOS, as since ABMC does not recognize revenues until the money hits the accounts per se, meaning they have a 60 day turnaround time, under GAAP guidelines, the aforementioned revenues will not be reflected until Q2. Additionally, channel checks have revealed that ABMC has signed NUMEROUS US DEALS, for millions of test kits domestically, numbering, conservatively in excess of ten million test kits. With a 43% profit margin, that means ABMC WILL MAKE $4.3 MILLION DOLLARS on this 10 million test kits. In addition, that does not account for the already 7.5 million test kits sold internationally by their distributors, which is in excess of 7.5 million test kits, meaning that ABMC will make an additional $3.2 million dollars. With the FDA/EUA approval now achieved, those sales are only going to grow exponentially.
Melissa or the company hasn’t given out sold Test kits and she isn’t saying 1M test kits have been sold, she wouldn’t and won’t give out numbers like that just yet, so this is what she said from the 8K,
As of the date of this release, we have recorded revenues of just over $1,000,000 which resulted in approximately $430,000 in profit to ABMC after expenses and commissions.
It’s not 1M test kits it’s only 1M in revenue which means the total test kits sold is around 200,000 assuming a price of $5.00 per test which would mean your projected numbers are way low like way low!
Please let me know if this is how you’re seeing it?
Also side note Bud Selig isn’t the commissioner anymore it’s Rob Manfred
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM